PriceTargets.com logo

ADMA Biologics - ADMA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.88
  • Forecasted Upside: 22.09%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 1 Strong Buy Ratings
$6.45 As of 04/25/2024 04:40 PM ET
▼ -0.01 (-0.15%)

This chart shows the closing price for ADMA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ADMA Biologics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ADMA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ADMA

Analyst Price Target is $7.88
▲ +22.09% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for ADMA Biologics in the last 3 months. The average price target is $7.88, with a high forecast of $10.00 and a low forecast of $6.00. The average price target represents a 22.09% upside from the last price of $6.45.

This chart shows the closing price for ADMA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in ADMA Biologics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/1/2022
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/30/2023
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/30/2023
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/29/2023
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2023
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2024
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2024

Latest Recommendations

  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/26/2024HC WainwrightReiterated RatingBuy ➝ Buy$6.00 ➝ $7.50Low
3/1/2024MizuhoBoost TargetBuy ➝ Buy$9.00 ➝ $10.00Low
2/29/2024Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$6.50 ➝ $8.00Low
2/29/2024HC WainwrightReiterated RatingBuy ➝ Buy$6.00Low
1/22/2024MizuhoBoost TargetBuy ➝ Buy$7.00 ➝ $9.00Low
1/9/2024HC WainwrightBoost TargetBuy ➝ Buy$5.00 ➝ $6.00Low
12/19/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$6.00Low
11/17/2023HC WainwrightReiterated RatingBuy ➝ Buy$5.00Low
8/10/2023Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$5.00 ➝ $6.00Low
8/10/2023Raymond JamesBoost TargetStrong-Buy ➝ Strong-Buy$5.00 ➝ $6.00Low
8/10/2023MizuhoBoost Target$6.00 ➝ $7.00Low
8/10/2023HC WainwrightBoost TargetBuy ➝ Buy$4.50 ➝ $5.00N/A
2/8/2023HC WainwrightReiterated RatingBuy$4.50Low
1/3/2023HC WainwrightBoost TargetBuy$4.00 ➝ $4.50Low
11/10/2022MizuhoBoost TargetBuy$5.00 ➝ $6.00Low
10/12/2022MizuhoInitiated CoverageBuy$5.00Low
7/25/2022HC WainwrightLower TargetBuy$6.00 ➝ $4.00Low
11/11/2021Raymond JamesUpgradeOutperform ➝ Strong-Buy$5.00High
11/8/2021Cantor FitzgeraldInitiated CoverageOverweight$4.50Medium
10/26/2021Raymond JamesLower TargetOutperform$6.00 ➝ $5.00High
10/8/2021Maxim GroupInitiated CoverageBuy$3.00Medium
9/20/2021Jefferies Financial GroupInitiated CoverageBuy$10.00Low
8/12/2021HC WainwrightLower TargetBuy$7.00 ➝ $6.00High
7/26/2021HC WainwrightReiterated RatingBuy$7.00High
7/6/2021HC WainwrightLower TargetBuy$10.00 ➝ $7.00High
4/5/2021Jefferies Financial GroupReiterated RatingBuy$10.00Low
3/26/2021Maxim GroupReiterated RatingBuy$6.00High
3/26/2021Raymond JamesLower TargetOutperform$7.00 ➝ $6.00High
1/4/2021HC WainwrightLower TargetBuy$12.00 ➝ $11.00N/A
10/1/2020Raymond JamesBoost TargetOutperform$7.00 ➝ $9.00High
8/6/2020HC WainwrightReiterated RatingBuy$12.00Low
8/6/2020OppenheimerInitiated CoverageBuy$6.00Low
7/28/2020HC WainwrightReiterated RatingBuy$12.00High
5/22/2020Maxim GroupInitiated CoverageBuy$6.00N/A
5/22/2020HC WainwrightReiterated RatingBuy$12.00N/A
5/7/2020OppenheimerLower TargetOutperform$14.00 ➝ $7.00High
3/16/2020HC WainwrightLower TargetBuy$14.00 ➝ $12.00High
1/8/2020HC WainwrightReiterated RatingBuyLow
11/20/2019HC WainwrightReiterated RatingBuy$13.00Low
10/21/2019Maxim GroupSet TargetBuy$12.00Low
8/27/2019Maxim GroupReiterated RatingBuy$12.00High
8/12/2019Dawson JamesDowngradeBuy ➝ Neutral$4.00High
6/25/2019OppenheimerSet TargetBuy$14.00High
6/4/2019Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$8.00Medium
5/23/2019HC WainwrightSet TargetBuy$13.00Medium
(Data available from 4/25/2019 forward)

News Sentiment Rating

1.10 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2023
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2023
  • 5 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2023
  • 7 very positive mentions
  • 6 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
12/27/2023
  • 8 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/26/2024
  • 10 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/25/2024
  • 14 very positive mentions
  • 23 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2024
  • 8 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024

Current Sentiment

  • 8 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

ADMA Biologics logo
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Read More

Today's Range

Now: $6.45
Low: $6.26
High: $6.49

50 Day Range

MA: $6.02
Low: $5.15
High: $6.74

52 Week Range

Now: $6.45
Low: $3.06
High: $6.76

Volume

952,410 shs

Average Volume

2,622,278 shs

Market Capitalization

$1.47 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.46

Frequently Asked Questions

What sell-side analysts currently cover shares of ADMA Biologics?

The following Wall Street research analysts have issued reports on ADMA Biologics in the last year: Cantor Fitzgerald, HC Wainwright, Mizuho, Raymond James, StockNews.com, and TheStreet.
View the latest analyst ratings for ADMA.

What is the current price target for ADMA Biologics?

4 Wall Street analysts have set twelve-month price targets for ADMA Biologics in the last year. Their average twelve-month price target is $7.88, suggesting a possible upside of 21.9%. Mizuho has the highest price target set, predicting ADMA will reach $10.00 in the next twelve months. Raymond James has the lowest price target set, forecasting a price of $6.00 for ADMA Biologics in the next year.
View the latest price targets for ADMA.

What is the current consensus analyst rating for ADMA Biologics?

ADMA Biologics currently has 3 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ADMA will outperform the market and that investors should add to their positions of ADMA Biologics.
View the latest ratings for ADMA.

What other companies compete with ADMA Biologics?

Other companies that are similar to ADMA Biologics include Inhibrx, Neumora Therapeutics, 4D Molecular Therapeutics, Sana Biotechnology and Autolus Therapeutics. Learn More about companies similar to ADMA Biologics.

How do I contact ADMA Biologics' investor relations team?

ADMA Biologics' physical mailing address is 465 STATE ROUTE 17, RAMSEY NJ, 07446. The biotechnology company's listed phone number is (201) 478-5552 and its investor relations email address is [email protected]. The official website for ADMA Biologics is www.admabiologics.com. Learn More about contacing ADMA Biologics investor relations.